UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 243

Sortiert nach

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

The New England journal of medicine, 2017-03, Vol.376 (11), p.1015-1026

2017

Link zum Volltext

Verfügbarkeit prüfen

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

Annals of oncology, 2019-06, Vol.30 (6), p.970-976

2019

Link zum Volltext

Verfügbarkeit prüfen

Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study

Annals of oncology, 2017-12, Vol.28 (12), p.3044-3050

2017

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy

Annals of oncology, 2012-05, Vol.23 (5), p.1241-1249

2012

Link zum Volltext

Verfügbarkeit prüfen

Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group

Journal of clinical oncology, 1999-11, Vol.17 (11), p.3461-3467

1999

Link zum Volltext

Verfügbarkeit prüfen

EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma

Annals of oncology, 2023-11, Vol.34 (11), p.1047-1054

2023

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up

Annals of oncology, 2023-03, Vol.34 (3), p.289-299

2023

Link zum Volltext

Verfügbarkeit prüfen

TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes

Annals of oncology, 2024-04, Vol.35 (4), p.392-401

2024

Link zum Volltext

Verfügbarkeit prüfen

Phase I Trial of Docetaxel With Estramustine in Androgen-Independent Prostate Cancer

Journal of clinical oncology, 1999-03, Vol.17 (3), p.958-967

1999

Link zum Volltext

Verfügbarkeit prüfen

A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer

Journal of translational medicine, 2006-01, Vol.4 (1), p.1-1, Article 1

2006

Link zum Volltext

Verfügbarkeit prüfen

Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone

Annals of oncology, 2017-01, Vol.28 (1), p.90-95

2017

Link zum Volltext

Verfügbarkeit prüfen

Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer

Annals of oncology, 2017-10, Vol.28 (10), p.2481-2488

2017

Link zum Volltext

Verfügbarkeit prüfen

Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer

Annals of oncology, 2020-07, Vol.31 (7), p.930-941

2020

Link zum Volltext

Verfügbarkeit prüfen

Chemotherapy for advanced hormone refractory prostate cancer

Urology (Ridgewood, N.J.), 1999-12, Vol.54 (6), p.30-35

Petrylak, Daniel P

1999

Link zum Volltext

Verfügbarkeit prüfen

Phase II/III study of rogaratinib versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma selected based on FGFR1/3 mRNA expression

Annals of oncology, 2018-10, Vol.29, p.viii331-viii331

2018

Link zum Volltext

Verfügbarkeit prüfen

EV-201: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy

Annals of oncology, 2018-10, Vol.29, p.viii326-viii327

2018

Link zum Volltext

Verfügbarkeit prüfen

EV-301: An open-label, randomized phase III study to evaluate enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC)

Annals of oncology, 2018-10, Vol.29, p.viii328-viii328

2018

Link zum Volltext

Verfügbarkeit prüfen

Docetaxel (Taxotere) in hormone-refractory prostate cancer

Seminars in oncology, 2000-04, Vol.27 (2 Suppl 3), p.24

Petrylak, D P

2000

Link zum Volltext

Verfügbarkeit prüfen

CTC-based biomarkers & PSMA-targeted imaging in patients with metastatic castrate-resistant prostate cancer (mCRPC)

Annals of oncology, 2018-10, Vol.29, p.viii294-viii294

2018

Link zum Volltext

Verfügbarkeit prüfen

Southwest Oncology Group Study of Paclitaxel and Carboplatin for Advanced Transitional-Cell Carcinoma: The Importance of Survival as a Clinical Trial End Point

Journal of clinical oncology, 2000-07, Vol.18 (13), p.2537-2544

2000

Link zum Volltext

Verfügbarkeit prüfen

Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T

Prostate cancer and prostatic diseases, 2014-09, Vol.17 (3), p.259-264

2014

Link zum Volltext

Verfügbarkeit prüfen

Rapid in Vivo Monitoring of Chemotherapeutic Response Using Weighted Sodium Magnetic Resonance Imaging

Clinical cancer research, 2000-06, Vol.6 (6), p.2146-2156

2000

Link zum Volltext

Verfügbarkeit prüfen

A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide

ESMO open, 2021-04, Vol.6 (2), p.100082-100082, Article 100082

2021

Link zum Volltext

Verfügbarkeit prüfen

Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer

Seminars in oncology, 1999-10, Vol.26 (5 Suppl 17), p.28-33

1999

Link zum Volltext

Verfügbarkeit prüfen

DEXAMETHASONE DOES NOT SIGNIFICANTLY CONTRIBUTE TO THE RESPONSE RATE OF DOCETAXEL AND ESTRAMUSTINE IN ANDROGEN INDEPENDENT PROSTATE CANCER

The Journal of urology, 2000-03, Vol.163 (3), p.834-837

2000

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 243

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(230)
Mit Volltextzugriff
(211)

Publikationsform

Sprache

Englisch
(243)
Japanisch
(19)

Erscheinungsjahr

n.n

Thema

Science & Technology
(110)
Life Sciences & Biomedicine
(106)
Humans
(104)
Male
(84)
Oncology
(64)
Biological And Medical Sciences
(46)
Medical Sciences
(45)
Aged
(44)
Middle Aged
(44)
Urology & Nephrology
(40)
Chemotherapy
(35)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(34)
Prostatic Neoplasms - Drug Therapy
(30)
Tumors
(27)
Aged, 80 And Over
(26)
Adult
(25)
Treatment Outcome
(24)
Female
(23)
Nephrology. Urinary Tract Diseases
(23)
Prostate Cancer
(23)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study

Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy

Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group

EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma

Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up

TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes

Phase I Trial of Docetaxel With Estramustine in Androgen-Independent Prostate Cancer

A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer

Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone

Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer

Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer

Chemotherapy for advanced hormone refractory prostate cancer

Phase II/III study of rogaratinib versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma selected based on FGFR1/3 mRNA expression

EV-201: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy

EV-301: An open-label, randomized phase III study to evaluate enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC)

Docetaxel (Taxotere) in hormone-refractory prostate cancer

CTC-based biomarkers & PSMA-targeted imaging in patients with metastatic castrate-resistant prostate cancer (mCRPC)

Southwest Oncology Group Study of Paclitaxel and Carboplatin for Advanced Transitional-Cell Carcinoma: The Importance of Survival as a Clinical Trial End Point

Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T

Rapid in Vivo Monitoring of Chemotherapeutic Response Using Weighted Sodium Magnetic Resonance Imaging

A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide

Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer

DEXAMETHASONE DOES NOT SIGNIFICANTLY CONTRIBUTE TO THE RESPONSE RATE OF DOCETAXEL AND ESTRAMUSTINE IN ANDROGEN INDEPENDENT PROSTATE CANCER

Suchergebnisse filtern